ZA201405746B - Rafamycin analogs and methods for making same - Google Patents
Rafamycin analogs and methods for making sameInfo
- Publication number
- ZA201405746B ZA201405746B ZA2014/05746A ZA201405746A ZA201405746B ZA 201405746 B ZA201405746 B ZA 201405746B ZA 2014/05746 A ZA2014/05746 A ZA 2014/05746A ZA 201405746 A ZA201405746 A ZA 201405746A ZA 201405746 B ZA201405746 B ZA 201405746B
- Authority
- ZA
- South Africa
- Prior art keywords
- rafamycin
- analogs
- methods
- making same
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/085631 WO2014082286A1 (fr) | 2012-11-30 | 2012-11-30 | Analogue de la rapamycine et procédés de fabrication associés |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201405746B true ZA201405746B (en) | 2015-11-25 |
Family
ID=50827071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2014/05746A ZA201405746B (en) | 2012-11-30 | 2014-08-04 | Rafamycin analogs and methods for making same |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2809675A4 (fr) |
JP (1) | JP2016500112A (fr) |
KR (1) | KR20150003156A (fr) |
CN (1) | CN104854112A (fr) |
AU (1) | AU2012395673A1 (fr) |
CA (1) | CA2863243A1 (fr) |
SG (1) | SG11201404432QA (fr) |
WO (1) | WO2014082286A1 (fr) |
ZA (1) | ZA201405746B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327097B (zh) * | 2014-10-11 | 2017-02-08 | 福建省微生物研究所 | 雷帕霉素的三氮唑衍生物和用途 |
CN104341434B (zh) * | 2014-10-16 | 2016-04-06 | 福建省微生物研究所 | 取代的雷帕霉素三氮唑衍生物和用途 |
CN104557975B (zh) * | 2014-12-23 | 2017-06-20 | 连云港恒运医药有限公司 | 依维莫司中间体及其降解杂质的制备方法 |
EP3061765B1 (fr) * | 2015-02-27 | 2018-01-31 | Warszawski Uniwersytet Medyczny | Dérivé de protoescigénine, son procédé de préparation, utilisation de ce composé et composition pharmaceutique comprenant ledit composé |
CN104876944B (zh) * | 2015-05-13 | 2017-11-10 | 普济生物科技(台州)有限公司 | 一种依维莫司的制备方法 |
EP3109250A1 (fr) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Procede pour la synthese de derives de rapamycine |
WO2017038925A1 (fr) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | Composition pharmaceutique contenant de la rapamycine ou un dérivé de celle-ci |
CN105481704A (zh) * | 2016-01-12 | 2016-04-13 | 西安近代化学研究所 | 一种键合剂n-炔丙基二乙醇胺的合成与提纯方法 |
CN107759616B (zh) * | 2016-08-23 | 2020-11-17 | 上海微创医疗器械(集团)有限公司 | 一种化合物及其制备方法和用途 |
IL288991B2 (en) * | 2017-04-05 | 2023-12-01 | Harvard College | A macrocyclic compound and its uses |
AU2018263886C1 (en) * | 2017-05-02 | 2022-12-22 | Revolution Medicines, Inc. | Rapamycin analogs as mTOR inhibitors |
CN109776569A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 一种依维莫司的制备方法 |
CN108484637A (zh) * | 2018-03-13 | 2018-09-04 | 福建省微生物研究所 | 靶向抗癌新药x-76成盐化合物及其用途、制备方法 |
IL278335B1 (en) | 2018-05-01 | 2024-05-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as MTOR inhibitors |
ES2945560T3 (es) | 2018-05-01 | 2023-07-04 | Revolution Medicines Inc | Análogos de rapamicina unidos en C40, C28 y C-32 como inhibidores de mTOR |
CN109776571B (zh) * | 2019-01-31 | 2021-06-11 | 哈药慈航制药股份有限公司 | 一种雷帕霉素类似物及其制备方法和应用 |
CN112057425A (zh) * | 2020-09-30 | 2020-12-11 | 严鹏科 | 一种雷帕霉素制剂及其制备方法 |
CN115160343B (zh) * | 2022-06-09 | 2023-11-14 | 福建省微生物研究所 | 一种雷帕霉素衍生物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
CN1235608A (zh) * | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
TW557297B (en) * | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
-
2012
- 2012-11-30 SG SG11201404432QA patent/SG11201404432QA/en unknown
- 2012-11-30 AU AU2012395673A patent/AU2012395673A1/en not_active Abandoned
- 2012-11-30 WO PCT/CN2012/085631 patent/WO2014082286A1/fr active Application Filing
- 2012-11-30 CN CN201280077424.7A patent/CN104854112A/zh active Pending
- 2012-11-30 EP EP12889107.4A patent/EP2809675A4/fr not_active Withdrawn
- 2012-11-30 CA CA2863243A patent/CA2863243A1/fr not_active Abandoned
- 2012-11-30 JP JP2015544291A patent/JP2016500112A/ja active Pending
- 2012-11-30 KR KR20147024024A patent/KR20150003156A/ko not_active Application Discontinuation
-
2014
- 2014-08-04 ZA ZA2014/05746A patent/ZA201405746B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN104854112A (zh) | 2015-08-19 |
WO2014082286A1 (fr) | 2014-06-05 |
KR20150003156A (ko) | 2015-01-08 |
AU2012395673A1 (en) | 2014-08-14 |
CA2863243A1 (fr) | 2014-06-05 |
AU2012395673A8 (en) | 2015-06-11 |
WO2014082286A9 (fr) | 2014-11-13 |
EP2809675A1 (fr) | 2014-12-10 |
EP2809675A4 (fr) | 2015-08-12 |
SG11201404432QA (en) | 2014-10-30 |
JP2016500112A (ja) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250690A1 (zh) | 方法 | |
ZA201405746B (en) | Rafamycin analogs and methods for making same | |
HK1208363A1 (en) | New methods | |
GB201212937D0 (en) | Method | |
GB201212932D0 (en) | Method | |
GB201213636D0 (en) | Method | |
GB201212934D0 (en) | Method | |
GB201210858D0 (en) | Method | |
GB2507760B (en) | Methods | |
EP2880048A4 (fr) | Procédé | |
GB201218570D0 (en) | Method | |
GB201208874D0 (en) | Methods | |
GB201202198D0 (en) | Method | |
GB201211393D0 (en) | Method | |
GB201204280D0 (en) | Methods | |
GB201217688D0 (en) | Method | |
GB201214029D0 (en) | method | |
GB201210147D0 (en) | Method | |
GB201208756D0 (en) | Methods | |
GB201213858D0 (en) | Method | |
GB201203337D0 (en) | Method | |
GB201201332D0 (en) | Method | |
EP2639418A4 (fr) | Procédé de chauffage d'échappement | |
GB201220686D0 (en) | Methods | |
AP2012000550S (en) | E-horn methods |